This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. HBM Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.119. HBM Holdings's 10-Year median PS Ratio is 0. Therefore, the Median PS Value for today is $0.00.
As of today (2024-05-31), HBM Holdings's share price is $0.482. HBM Holdings's Median PS Value is $0.00. Therefore, HBM Holdings's Price to Median PS Value for today is 0.00.
The historical rank and industry rank for HBM Holdings's Median PS Value or its related term are showing as below:
HBMHF's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.67 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
HBM Holdings Median PS Value Historical Data
The historical data trend for HBM Holdings's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of HBM Holdings's Median PS Value
For the Biotechnology subindustry, HBM Holdings's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HBM Holdings's Price-to-Median-PS-Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HBM Holdings's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where HBM Holdings's Price-to-Median-PS-Value falls into.
HBM Holdings Median PS Value Calculation
HBM Holdings's Median PS Value for today is calculated as
10-Year Median PS Ratio is 0.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. HBM Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.119.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HBM Holdings (OTCPK:HBMHF) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
HBM Holdings's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
0.482
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HBM Holdings Median PS Value Related Terms
Thank you for viewing the detailed overview of HBM Holdings's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its products under development are Batoclimab, for the treatment of a wide spectrum of autoimmune diseases; Tanfanercept, for the treatment of moderate-to-severe dry eye disease (DED); HBM4003; HBM9378, to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus; HBM7008; and others. Its geographical segments are Mainland China, United States, Europe, and others. Majority of revenue is generated from Europe.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HBMHF has been successfully added to your 